Finerenone shows superior survival and kidney protection over spironolactone in diabetic kidney disease
Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), significantly reduces the risk ...
Nov 26, 2025
0
0









